Zoetis (ZTS) announced it has entered into a definitive agreement with Neogen (NEOG) to acquire Neogen’s animal genomics business for $160M, subject to customary closing adjustments. The deal is subject to customary closing conditions and the satisfaction of regulatory requirements, and Zoetis expects to complete the acquisition in the second half of calendar year 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis: VMD Review Reinforces Librela Safety Profile and Supports Buy-Rated Growth Outlook
- Zoetis Earnings Call: Growth Holds Amid Competitive Strain
- Zoetis’ Convertible Notes Trigger Liquidity and Reporting Risks if Conditional Conversion Kicks In
- Zoetis price target raised to $140 from $135 at BofA
- Morning Movers: Fastly skyrockets following fourth quarter results